Corvus Pharmaceuticals Inc. (NASDAQ: (CRVS) stock plunged by 6.14% at last close while the CRVS stock-price declines by 2.13% in the pre-market trading session. Corvus Pharmaceuticals is a pharmaceutical firm in the early stages of development. Mupadolimab (CPI-006), a humanised monoclonal antibody directed against CD73 that has shown immunomodulatory action and immune cell activation in preclinical investigations, is Corvus’ primary product candidate.
CRVS stock’ Update
Corvus Pharmaceuticals updated on its mupadolimab development projects in cancer and infectious illness (formerly CPI-006). It’s a humanised monoclonal antibody that targets CD73 and is thought to activate B cells in two ways. It aids in the generation of immunological responses to viruses and tumour antigens, as well as the inhibition of immunosuppressive adenosine synthesis in the tumour microenvironment.
Starting with COVID-19, Corvus is producing mupadolimab as a treatment for oncology and infectious disease applications. The findings of the Company’s Phase 3 clinical study of mupadolimab for COVID-19 have been posted online at medRxiv.org. The findings, which include 40 patients who were recruited in the trial before it was voluntarily stopped, show that single doses of mupadolimab at 2mg/kg and 1mg/kg improved the primary and crucial secondary endpoints as compared to placebo. In the study, no drug-related negative events were recorded.
Richard A. Miller, co-founder, president and CEO of Corvus stated,
Mupadolimab is among the most extensively researched anti-CD73 antibodies, with a possible dual mechanism of B cell activation and immunosuppressive adenosine inhibition. Immune responses to viral antigens and tumour antigens might be improved as a consequence of the complimentary processes. They think that by eliminating the adenosine-mediated inhibition of the immune system and boosting immunological responses through B cell activation, they will be capable of developing a novel method to treating malignancies. At the SITC meeting in November, they want to share fresh results from their Phase 1b/2 oncology research.
